Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy
Overview
Authors
Affiliations
Radiopharmaceutical therapy (RPT) has grown rapidly over the last decade for treatment of numerous cancer types. Dosimetric guidance, as with other radiotherapy modalities, has benefitted patients by reducing the incidence of side effects and improving overall survival in populations treated under this paradigm. Development of tools and techniques for dosimetry-guided therapy is ongoing, with numerous the Food and Drug Administration-cleared products reaching the U.S. market in 2019. Safe use of commercial dosimetry platforms requires a deep understanding of the underlying physical principles and thoroughly vetted input data. Likewise, interpretation of dosimetry results relies on an understanding of radiobiological principles, and the principles of uncertainty propagation. In this article, we review strategies commonly employed for dosimetry-guided RPT - including quantitative imaging, dose calculation methods, and modeling of dose across time-points. Additionally, we review recent literature evidence (2013-2020) demonstrating the efficacy of personalized RPT.
Zaid N, Bastiaannet R, Hobbs R, Sgouros G J Nucl Med. 2025; 66(1):84-90.
PMID: 39753362 PMC: 11705791. DOI: 10.2967/jnumed.124.268457.
Advancing the Collaboration Between Imaging and Radiation Oncology.
Jia X, Carter B, Duffton A, Harris E, Hobbs R, Li H Semin Radiat Oncol. 2024; 34(4):402-417.
PMID: 39271275 PMC: 11407744. DOI: 10.1016/j.semradonc.2024.07.005.
Abdollahi H, Yousefirizi F, Shiri I, Brosch-Lenz J, Mollaheydar E, Fele-Paranj A Theranostics. 2024; 14(9):3404-3422.
PMID: 38948052 PMC: 11209714. DOI: 10.7150/thno.93973.
Kim K, Byun B, Lim I, Lim S, Woo S Diagnostics (Basel). 2023; 13(19).
PMID: 37835788 PMC: 10572561. DOI: 10.3390/diagnostics13193045.
Jahn U, Garske-Roman U, Sandstrom M, Lubberink M, Sundin A EJNMMI Res. 2023; 13(1):45.
PMID: 37204528 PMC: 10199148. DOI: 10.1186/s13550-023-00997-0.